rgx-314
Gene therapyexperimental
Clinical trial activity
9 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
3
Phase 4
0
Earliest trial started Mar 31, 2017 (NCT03066258)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rgx-314
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07007065 | Phase 3 | Nov 5, 2025 | AbbVie |
| NCT06942520 | Phase 2 | Mar 18, 2025 | Regenxbio Inc., Sierra Eye Associates |
| NCT05407636 | Phase 3 | Dec 28, 2021 | Regenxbio Inc. |
| NCT04832724 | Phase 2 | Feb 22, 2021 | Regenxbio Inc. |
| NCT04704921 | Phase 2/Phase 3 (Phase 3) | Dec 29, 2020 | Regenxbio Inc. |
| NCT04567550 | Phase 2 | Nov 20, 2020 | Regenxbio Inc. |
| NCT04514653 | Phase 2 | Aug 13, 2020 | Regenxbio Inc. |
| NCT03999801 | Phase 2 | May 31, 2019 | AbbVie |
| NCT03066258 | Phase 1 | Mar 31, 2017 | Ophthalmic Consultants of Boston, Regenxbio Inc. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regenxbio Inc. | For profit | 7 | 6 | 3 | 2017 |
| AbbVie | For profit | 2 | 2 | 2 | 2019 |
| Ophthalmic Consultants of Boston | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Sierra Eye Associates | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1